Aristides Capital’s Adicet Bio ACET Stock Holding History

Aristides Capital’s Portfolio ACET Stock Details ACET Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2020 Q1	–	Sell	-1,352	Closed	-$226K	–	159
2019 Q4	$226K	Buy	+1,352	New	+$684K	0.18%	146

Other funds holding ACET

OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Baillie Gifford & Co Edinburgh, United Kingdom $97.9B AUM 20.73% 1-Year Est. Return

Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Ruffer LLP London, United Kingdom $2.44B AUM 44.75% 1-Year Est. Return

Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return

Aristides Capital's ACET Position: Q1 2020 in Review

Aristides Capital sold out of Adicet Bio (ACET) in Q1 2020, closing a stake of 1,352 shares — an estimated $226K sold.

Aristides Capital first reported a position in ACET in Q4 2019 and held it in 1 quarter. The position peaked at $226K in Q4 2019. 51 funds tracked by Wall St. Rank hold ACET as of Q1 2020.

Aristides Capital reported no remaining Adicet Bio position as of Q1 2020 after selling out during the quarter.
Aristides Capital sold 1,352 Adicet Bio shares in Q1 2020, an estimated $226K.
Aristides Capital first reported a position in Adicet Bio in Q4 2019 and held it in 1 quarter.
Aristides Capital's Adicet Bio position peaked at $226K in Q4 2019.
51 funds tracked by Wall St. Rank held Adicet Bio as of Q1 2020.

Based on Aristides Capital's 13F filing for Q1 2020, filed 15 May 2020.